Ixovex 1
Alternative Names: Ixovex-1Latest Information Update: 03 Mar 2025
At a glance
- Originator PsiVac
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 17 Dec 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in United Kingdom (Intratumoural) (NCT06549946)
- 17 Dec 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Monotherapy) in United Kingdom (Intratumoural) (NCT06549946)